Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PROF | US
-2.18
-29.11%
Healthcare
Diagnostics & Research
30/06/2024
06/03/2026
5.31
6.51
6.73
5.19
Profound Medical Corp. together with its subsidiaries operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada Germany the United States and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI) robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise flexible and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve which combines real-time MRI and thermometry for the treatment of uterine fibroids palliative pain treatment of bone metastases and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga Canada.
View LessStrong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
148.3%1 month
112.0%3 months
82.1%6 months
80.5%-
-
4.83
-
-
-5.75
20.62
-
-29.97M
130.51M
130.51M
-
-350.78
-
39.40
-66.00
4.65
2.71
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.80
Range1M
2.80
Range3M
3.76
Rel. volume
9.01
Price X volume
10.53M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Common Stock | BNGO | Diagnostics & Research | 1.12 | 96.32M | -0.88% | 0.03 | 34.32% |
| Anixa Biosciences Inc | ANIX | Diagnostics & Research | 2.85 | 91.71M | -1.38% | n/a | 1.09% |
| Co-Diagnostics Inc | CODX | Diagnostics & Research | 2.11 | 67.33M | -9.44% | n/a | 3.57% |
| Sera Prognostics Inc. | SERA | Diagnostics & Research | 1.95 | 65.07M | -2.50% | n/a | 2.27% |
| ENDRA Life Sciences Inc | NDRA | Diagnostics & Research | 3.36 | 61.79M | -2.04% | n/a | 3.13% |
| Cytosorbents Corporation | CTSO | Diagnostics & Research | 0.798 | 43.43M | -0.88% | n/a | 159.92% |
| Neuronetics Inc | STIM | Diagnostics & Research | 1.38 | 41.82M | -2.13% | n/a | 323.03% |
| Precipio Inc | PRPO | Diagnostics & Research | 26.5342 | 39.33M | 0.05% | n/a | 9.66% |
| BioTelemetry Inc | BEAT | Diagnostics & Research | 1.4 | 37.19M | 0.00% | n/a | 0.00% |
| STAR EQUITY HOLDINGS INC | STRR | Diagnostics & Research | 10.07 | 32.44M | 0.20% | n/a | 26.85% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 41.85 | 120.19M | 2.07% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.25 | 101.81M | -0.95% | 9.09 | 39.79% |
| Reading International Inc | RDIB | Media - Diversified | 11.55 | 90.60M | -5.17% | n/a | 4054.78% |
| ILAG | ILAG | Building Products & Equipment | 2.4783 | 44.76M | 6.82% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.21 | 32.29M | -3.49% | 0.03 | 16.03% |
| Reading International Inc | RDI | Media - Diversified | 0.9993 | 28.21M | -2.98% | n/a | 4054.78% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6345 | 12.26M | -10.63% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.4799 | 3.78M | -0.68% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.397 | 3.78M | -1.73% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -3.24% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.75 | - | Cheaper |
| Ent. to Revenue | 20.62 | - | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 4.83 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 82.14 | - | Riskier |
| Debt to Equity | - | -14.36 | - |
| Debt to Assets | - | 0.34 | - |
| Market Cap | 130.51M | - | Emerging |